Kaohsiung Chang Gung Memorial Hospital
Research in hepatocellular carcinoma provides new insights
Published in Hospital Business Week, November 20th, 2005
Study 1: Sustained response to hepatitis C therapy extends survival after liver tumor ablation.
According to recent research from Taiwan, "antiviral therapy for chronic hepatitis C virus (HCV) infection has led to a reduction in the incidence of hepatocellular carcinoma (HCC). The purpose of the present paper was to assess whether antiviral therapy might suppress tumor recurrence and influence overall survival in patients with HCV-related HCC who had complete ablation of nodules by non-surgical treatments."
"Twenty patients with 3 or fewer nodules...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
More Articles from Hospital Business Week
- Dartmouth Medical School
Health cost disparity is partly due to physician behavior - Esprit Pharma, Inc.
Pharmaceutical company gets exclusive North American rights to Estrasorb topical emulsion - Forest Laboratories, Inc.
Lexapro maker reports second-quarter earnings per share of $0.59 - Henry Schein, Inc.
Surgical supplier reports earnings per share of $0.41 - Illumina, Inc.
Children's hospital to participate in study of single nucleotide polymorphisms - MedSynergies, Inc.
Financial and technology services provider introduces claims intelligence system - More from this issue of Hospital Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
